1. Lozada C, Steigelfest E. Osteoarthritis. Medicine Rheumatology. 2010;15:12-23.
2. Raynauld JP, Martel-Pelletier J, Haraoui B, Pelletier JP. Chapter 25. Osteoarthritis-arthrosis short term studies: pain and function improvement in Osteoarthritis 2002, pages 294-306.
3. Garstang SV, Stitik TP. Osteoarthritis: epidemiology, risk factors, and pathophysiology. Am J Phys Med Rehabil. 2006;85:S2–S11.
4. Tsumura H, Tamura I, Tanaka H, et al. Prescription of non-steroidal anti-inflammatory drugs and co-prescribed drugs for mucosal protection: analysis of the present status based on questionnaires obtained from orthopaedists in japan. Inter Med. 2007;46:927-931.
5. Goldring SR, Goldring MB. Clinical aspects, pathology and pathophysiology of osteoarthritis. J Musculoskelet Neuronal Interact. 2006; 6:376-378.
6. Bierma-Zeinstra SM, Koes BW. Risk factors and prognostic factors of hip and knee osteoarthritis. Nat Clin Pract Rheumatol. 2007;3:78-85.
7. Goldring MB, Goldring SR. Osteoarthritis. J Cell Physiol. 2007;213:626–634.
8. Martel-Pelletier J. Pathophysiology of osteoarthritis. Osteoarthritis Cartilage. 2004;12:S31-S33.
9. Chevalier X, Mugnier B, Bouvenot G, Chevalier X, Mugnier B, Bouvenot G. Targeted anti-cytokine therapies for osteoarthritis. Bull Acad Nationale Medecine. 2006;190:1411-1420.
10. Roddy E, Doherty M. Changing life-styles and osteoarthritis: what is the evidence?. Best Pract Res Clin Reumatol. 2006;20:81-97.
11. Lee YC, Shmerling RH. The benefit of nonpharmacologic therapy to treat symptomatic osteoarthritis. Curr Rheumatol Rep. 2008;10:5-10.
12. Zhang W, Moskowitz RW, Nuki G, et al. OARSI Recommendations for the management of hip and knee osteoarthritis. part I: critical appraisal of existing treatment guidelines and systematic review of current research evidence. Osteoarthritis Cartilage. 2007;15:981-1000.
13. Zhang W, Moskowitz R, Nuki G, et al. OARSI recommendations for the management of hip and knee osteoarthritis, Part II: OARSI evidence-based, expert consensus guidelines. Osteoarthritis Cartilage. 2008;16:137-162.
14. Bannwarth B. Acetaminophen or NSAIDs for the treatment of osteoarthritis. Best Pract Res Clin Rheumatol. 2006;20:117-129.
15. Kobayakawa M, Uemura N. Prevention and treatment of non-steroidal anti-inflammatory drugs induced ulcers in osteoarthritis. Nippon Rinsho. 2007;65:1857-1861.
16. Scanzello CR, Moskowitz NK, et al. The post-NSAID era: what to use now for the pharmacologic treatment of pain and inflammation in osteoarthritis. Curr Rheumatol Rep. 2008;10:49-56.
17. Mikhail SS, Zwar NA, Vagholkar S, Dennis SM, Day RO. Non-steroidal anti-inflammatory drugs in general practice: a decision-making dilemma. Med J Aust. 2007;187:160-163.
18. Yajima H, Yamao J, Fukui H, Takakura Y. Up-to-date information on gastric mucosal lesions from long-term NSAID therapy in orthopaedic outpatients: a study using logistic regression analysis. J Orthop Sci. 2007;12:341-346.
19. Mitchell J, Warner T. Discontinuation of Vioxx. Lancet. 2004;365:27-28.
20. Graham DJ, Campen D, Hui R, et al. Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case-control study. Lancet. 2005;365:475-481.
21. Kimmel SE, Berlin JA, Reilly M, et al. Patients exposed to rofecoxib and celecoxib have different odds of nonfatal myocardial infarction. Ann Intern Med. 2005;142:157-164.
22. Lamarque D. Pathogenesis of gastroduodenal lesions induced by non-steroidal anti-inflammatory drugs. Gastroenterol Clin Biol. 2004;28:C18-C26.
23. Whittle BJ. Gastrointestinal effects of non-steroidal anti-inflammatory drugs. Fundam Clin Pharmacol. 2003;17:301-313.
24. Kountouras J, Chatzopoulos D, Zavos C. Reactive oxygen metabolites and upper gastrointestinal diseases. Hepatogastroenterology. 2001;48:743-751.
25. Demir S, Yilmaz M, Koseoglu M, Akalin N, Aslan D, Aydin A. Role of free radicals in peptic ulcer and gastritis. Turkish J. Gastroenterology. 2003;14:39-43.
26. Pohle T, Brzozowski T, Becker JC, Van Der Voort IR, et al. Role of reactive oxygen metabolites in aspirin-induced gastric damage in humans: gastroprotection by vitamin C. Aliment Pharmacol Ther. 2001;15:677–687.
27. Lin J., Zhang W. et al. Efficacy of topical non-steroidal anti-inflammatory drugs in the treatment of osteoarthritis: meta-analysis of randomised controlled trials. BMJ. 2004;329:324.
28. Cepeda MS, Camargo F. Tramadol for osteoarthritis. Cochrane Database Syst Rev. 2006; CD005522.
29. Towheed TE, Maxwell L, Judd M, Cotton M, Huchberg MC, Wells GA. Acetaminophen for osteoarthritis. Cochrane Database Syst Rev. 2006; January 25 (1):CD004257.
30. Strauss EJ, Hart JA, Miller MD, Altman RD, Rosen JE. Hyaluronic acid viscosupplementation and osteoarthritis: current uses and future directions. Am J Sports Med. 2009;37:1636-1644.
31. Reginster JY, Deroisy R, Rovati LC, et al. Long-term effects of glucosamine sulphate on osteoarthritis progression: a randomised, placebo-controlled clinical trial. Lancet. 2001;357:251-256.
32. Pavelka K, Gatterova J, Olejarova M, et al. Glucosamine sulphate use and delay of progression of knee osteoarthritis: a 3-year, randomized, placebo-controlled, double-blind study. Arch Intern Med. 2002;162:2113-2123.
33. McAlindon T: Why are clinical trials of glucosamine no longer uniformly positive? Rheum Dis Clin North Am. 2003;29:789-801.
34. McAlindon TE, Formica M, LaValley M, et al. Effectiveness of glucosamine for symptoms of knee osteoarthritis: results from an internet-based randomized double-blind controlled trial. Am J Med. 2004;117:643-649.
35. Huskisson EC. Glucosamine and chondroitin for osteoarthritis. J Int Med Res. 2008;36:1161-1179.
36. Piscoya J, Rodríguez Z, Bustamante SA, et al. Efficacy and safety of freeze-dried cat's claw in osteoarthritis of the knee: mechanisms of action of the species Uncaria guianensis. Inflamm Res. 2001;50:442-448.
37. Ahmed S, Rahman A, Hasnain A, et al. Green tea polyphenol epigallocatechin-3-gallate inhibits the IL-1β-induced activity and expression of cyclo-oxygenase-2 and nitric oxide synthase-2 activity in human chondrocytes. Free Radical Biology Med. 2002;33:1097-1105.
38. Walter-Bone K: 'Natural remedies' in the treatment of osteoarthritis. Drugs & Aging. 2003;20:517-526.
39. Miller M, Mehta K, Kunte S, et al. Early relief of osteoarthritis symptoms with a natural mineral supplement and a herbomineral combination: a randomized controlled trial. J Inflamm. 2005;2:11-17.
40. Frestedt JL, Walsh M, Koskowski M, Zenk J. A natural mineral supplement provides relief from knee osteoarthritis symptoms: a randomized, controlled pilot trial. Nutrition J. 2008;7:9-13.
41. Cisar P. Effect of pine bark extract (Pycnogenol) on symptoms of knee osteoarthritis. Phytoher Res. 2008;22:518-523.
42. Frech TM, Clegg DO. The utility of nutraceuticals in the treated of osteoarthritis. Rheumatol Rep. 2007;9:25-30.
43. Mas R. Abexol: Beeswax alcohols. Drugs of the Future. 2001;26:731-744.
44. Menéndez R., Amor AM, González RM, et al. Inhibition of rat microsomal lipid peroxidation by the oral administration of Abexol. Brazil J Med Biol Res. 2000;33:85-90.
45. Molina V, Valdés S, Carbajal D, et al. Antioxidant effects of Abexol on gastric mucosa of rats with injury induced experimentally. J Med Food. 2001;4:79-84.
46. Pérez Y, González R, Amor AM, et al. Abexol on antioxidant enzymes in liver and brain of rats. Rev CENIC Cien Biol. 2002;33:3-5.
47. Mendoza S, Noa M, Perez Y, Más R. Preventive effect of Abexol, a mixture of long-chain alcohols from beeswax, on the liver damage induced with CCl4 in rats. J Med Food. 2007;10:379-383.
48. Menéndez R, Más R, Amor AM, et al. Antioxidant effects of Abexol on the in vitro susceptibility in healthy volunteers. Arch Med Res. 2001;32:436-441.
49. Menéndez R, Más R, Illnait J, et al. Effects of Abexol on lipid peroxidation in older subjects. J Med Food. 2001;4:71-77.
50. López E, Illnait J, Molina V, et al. Effects of Abexol (beeswax alcohols) on lipid peroxidation in middle-aged and older subjects. LAJP. 2008;27:695-703.
51. Rodriguez I, Illnait J, Molina V, et al. Comparison of the antioxidant effects of Abexol (beeswax alcohols) and grape seed extract (GSE) on plasma oxidative variables in healthy subjects LAJP. 2009;4:21-26.
52. Carbajal D, Molina V, Valdés S, et al. Anti-inflammatory activity of Abexol: an active product isolated from beeswax. Prostag Leuk Essent Fatty Acids. 1998;59:235-238.
53. Ravelo Y, Molina V, Carbajal D, et al. Effects of single oral and topical administration of D-002 (beeswax alcohols) on xylene induced ear edema in mice. LAJP. 2010;29:107-112.
54. Ravelo Y, Molina V, Carbajal D, et al. Evaluation of anti-inflammatory and antinociceptive effects of Abexol (beeswax alcohols). J Nat Med. 2010;65:330-335.
55. Mendoza S, Noa M, Valle M, Mendoza N, Más R. Effects of D-002 on formaldehyde-induced osteoarthritis in rats. Int. Org. Sci. Res. 2013 (in press)
56. Mendoza S, Noa M, Valle M, Mendoza N, Más R. Ameliorating effects of D-002, a mixture of beeswax alcohols, on monosodium iodoacetate-induced osteoarthritis in rats. Int. J. PSRR, 2013; 19:10-15.
57. Rodríguez I, Illnait J, Fernández L, Fernández JC, Mendoza S, Gamez R, Mesa M, Más R. Effects of D-002, a mixture of beeswax alcohols, on osteoarthritis symptoms: a randomized placebo-controlled study. Journal of Pharmacy. 2012;2:10-16
58. Estudio de los efectos anti-inflamatorios del Abexol sobre los síntomas de la osteoartritis. Datos de archivo.
59. Pérez Y, Oyarzábal A, Ravelo Y, Mas R, Jiménez S, Molina V. Inhibition of COX and 5-LOX enzymes by D-002 (beeswax alcohols). Current Top Nutraceutical Research 2012; 6:18-25.
60. Carbajal D, Molina V, Valdés S, et al. Anti-ulcer activity of higher primary alcohols of beeswax. J Pharm Phamacol. 1995;47:731-733.
61. Carbajal D, Molina V, Valdés S, et al. Possible cytoprotective mechanism in rats of Abexol an anti-ulcerogenic product isolated from beeswax. J Pharm Pharmacol. 1996;48:858-860.
62. Carbajal D, Molina V, Noa M, et al. Effects of Abexol on gastric mucus composition in ethanol induced ulcer. Pharmacol Res. 2000;42:329-332.
63. Illnait J, Terry H, Más R, et al. Effects of Abexol, a product isolated from beeswax, on gastric symptoms of patients with osteoarthritis treated with piroxicam: a pilot study. J Med Food. 2005; 8:63-68.
64. Rodríguez I, Illnait J, Terry H, et al. Effects of Abexol (beeswax alcohols) on the gastrointestinal symptoms of middle-aged and elderly subjects. Rev CENIC Cien Biol. 2009;40:3-8.
65. Hano O, Illnait J, Más R, et al. Effects of Abexol, a product isolated from beeswax, on duodenal ulcer: A double-blind, placebo-controlled study. Curr Ther Res. 2001;62:394-407.
66. Fernández JC, Rodríguez I, Illnait J, Fernández L, Mas R, Pérez Y, Gámez R, Mesa M, Jiménez S, Mendoza S, Ruiz D. Effects of Abexol (beeswax alcohols) in patients with gastric symptoms. Rev CENIC Cien Biol. 2012;43:9-16.
67. Fernández L, Terry H, Quiñones AM, et al. Effects of Abexol in middle-aged and older subjects: an open follow-up. Rev CENIC Cien Biol. 2008;39:3-8.
68. Rodeiro I, Alemán C, Noa M, et al. Preclinical oral toxicology in rats of Abexol, a natural drug with antiulcer effects. Drug Chem Tox. 1998;21:151-163.
69. Rodeiro I, Gámez R, Acosta PC, et al. Estudio genotoxico del Abexol, un producto con actividad antiulcerosa Rev Esp Tox. 1998;15:117-121.
70. Rodríguez MD, Gámez R, Sánchez M, García H. Developmental toxicity of Abexol, a mixture of aliphatic primary alcohols in rats and rabbits. J Appl Toxicol. 1998;18:313-316.
71. Rodeiro I, Alemán C, Noa M, et al. Oral toxicological studies of Abexol in mice. Rev CENIC Cien Biol. 1999;30:73-75.
72. Alemán C, Rodeiro I, Noa M, et al. A one-year study of Abexol. a mixture of aliphatic primary alcohols in Beagle dogs. J Appl Toxicol. 2000;20:427-432.
73. Doggrell SA. Lyprinol-is it a useful anti-inflammatory agent? Evid Based Complement Alternat Med. 2011; 307121. Epub 2011 Aug 11.
74. McPhee S, Hodges LD, Wright PFA. Anti-cyclooxygenase effects of lipid extracts from the New Zealand green-lipped mussel, Perna canaliculus. Comparative Biochemistry and Physiology. 2007;146:346–356.
75. Halpern GM. Review Anti-inflammatory effects of a stabilized lipid extract of Perna canaliculus (Lyprinol). Allerg Immunol. 2000;32:272-278.
76. Lee C-H, Lum JH-K, Ng CK-C. Pain controlling and Cytokine-regulating effects of lyprinol, a lipid extract of perna canaliculus, in a rat Adjuvant-induced arthritis model. Evidence-Based Complementary and Alternative Medicine. 2009;6:239–245.
77. Singh M, Hodges LD, Wright PFA. The CO2-SFE crude lipid extract and the free fatty acid extract from Perna canaliculus have anti-inflammatory effects on adjuvant-induced arthritis in rats. Comparative Biochemistry and Physiology B. 2008;149:251–258.
78. Hielm-Björkman A, Tulamo R-M, Salonen H, Raekallio M. Evaluating complementary therapies for canine osteoarthritis part I: green-lipped mussel (Perna canaliculus) Evidence-Based Complementary and Alternative Medicine. 2009; 6:365–373.
79. Treschow AP, Hodges LD, Wright PFA, Wynne PM, Kalafatis N, Macrides TA. Novel anti-inflammatory ω-3 PUFAs from the New Zealand green-lipped mussel, Perna canaliculus. Comparative Biochemistry and Physiology B. 2007; 147:645–656.
80. Emelyanov A, Fedoseev G, Krasnoschekova O, Abulimity A, Trendeleva T, Barnes PJ. Treatment of asthma with lipid extract of New Zealand green-lipped mussel: a randomised clinical trial. Eur Respir J. 2002 20:596-600.
81. Gruenwald J, Graubaum HJ, Hansen K, Grube B. Efficacy and tolerability of a combination of Lyprinol and high concentrations of EPA and DHA in inflammatory rheumatoid disorders. Advances in Therapy. 2004;21:197-201.
82. Cobb CS, Ernst E. Review Systematic review of a marine nutraceutical supplement in clinical trials for arthritis: the effectiveness of the New Zealand green-lipped mussel Perna canaliculus. Clin Rheumatol. 2006;25:275-284.
83. Coulson S, Vecchio P, Gramotnev H, Vitetta L. Green-lipped mussel (Perna canaliculus) extract efficacy in knee osteoarthritis and improvement in gastrointestinal dysfunction: a pilot study. Inflammopharmacology. 2012; 20:71-76.
84. Cho SH, Jung YB, Seong SC. Clinical efficacy and safety of Lyprinol®, a patented extract from New Zealand green-lipped mussel (Perna Canaliculus) in patients with osteoarthritis of the hip and knee: a multicenter 2-month clinical trial. European Annals of Allergy and Clinical Immunology. 2003;35:212–216.
85. Pollard B, Guilford WG, Ankenbauer-Perkins KL, Hedderley D. Clinical efficacy and tolerance of an extract of green-lipped mussel (Perna canaliculus) in dogs presumptively diagnosed with degenerative joint disease. New Zealand Veterinary Journal. 2006;54(3):114–118.
86. Shiels I-A, Whitehouse M-W. Lyprinol: anti-inflammatory and uterine-relaxant activities in rats, with special reference to a model for dysmenorrhoea. Allergie et Immunologie. 2000;32(7):279–283.
87. Batlle-Gualda E, Esteve-Vives J, Piera MC, Hargreaves R, Cutts J. Adaptación transcultural al cuestionario WOMAC especifico para artrosis de rodilla y cadera. Rev Esp Reumatol. 1999;26:38-45.
88. Angst T, Aeschlimann A, Stuki G. Smallest detectable and minimal clinically important differences of rehabilitation intervention with their implication for required sample sizes using WOMAC and SF-36 quality of life measurement instruments in patients with osteoarthritis of the lower extremities. Arthritis and Rheumatism. 2001;45:384-391.
89. Nipanikar S, Saluja M, Kuber V, Kadbhane K, Chopra A, Khade N. An open label, prospective, clinical study on a polyherbal formulation in osteoarthritis of knee. J Ayurveda Integr Med. 2013 Jan-Mar; 4(1): 33–39.
90. Fardellone P, Zaim M, Saurel AS, Maheu E. Comparative Efficacy and Safety Study of Two Chondroitin Sulfate Preparations from Different Origin (Avian and Bovine) in Symptomatic Osteoarthritis of the Knee. Open Rheumatol J. 2013; 7: 1–12.
91. Altman R, Asch E, Bloch D, et al. The American College of Rheumatology Criteria for the classification and reporting of osteoarthritis of the knee. Arthritis Rheum. 1986;9:1039-1049
92. Altman R, Alarcón G, Appelrouth D, et al. The American College of Rheumatology Criteria for the classification and reporting of osteoarthritis of the hip. Arthritis Rheum. 1991;34:505-514.
93. Requerimientos para la notificación y el reporte de eventos adversos graves e inesperados en los ensayos clínicos. Regulación No. 45-2007. CECMED, 2007.